Italy · Delayed Price · Currency is EUR TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of EUR 4.40 billion. The enterprise value is 4.40 billion.
| Market Cap | 4.40B |
| Enterprise Value | 4.40B |
Important Dates
The last earnings date was Monday, November 3, 2025.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 145.90M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.64% |
| Shares Change (QoQ) | -0.96% |
| Owned by Insiders (%) | 7.32% |
| Owned by Institutions (%) | 72.58% |
| Float | 135.16M |
Valuation Ratios
The trailing PE ratio is 11.54 and the forward PE ratio is 18.36.
| PE Ratio | 11.54 |
| Forward PE | 18.36 |
| PS Ratio | 9.70 |
| PB Ratio | 18.67 |
| P/TBV Ratio | 18.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 11.54 |
| EV / Sales | 9.54 |
| EV / EBITDA | 49.09 |
| EV / EBIT | 49.40 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 2.48 |
| Debt / FCF | n/a |
| Interest Coverage | 3.77 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.15% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 1.23M |
| Profits Per Employee | 1.03M |
| Employee Count | 338 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -306.59M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 28.60 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 60.48 |
| Average Volume (20 Days) | 4 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 10.81 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of EUR 453.34 million and earned 381.38 million in profits. Earnings per share was 2.37.
| Revenue | 453.34M |
| Gross Profit | 386.88M |
| Operating Income | 87.60M |
| Pretax Income | 74.79M |
| Net Income | 381.38M |
| EBITDA | 87.64M |
| EBIT | 87.60M |
| Earnings Per Share (EPS) | 2.37 |
Balance Sheet
The company has 214.67 million in cash and 216.93 million in debt, giving a net cash position of -2.26 million.
| Cash & Cash Equivalents | 214.67M |
| Total Debt | 216.93M |
| Net Cash | -2.26M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 235.60M |
| Book Value Per Share | 1.62 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 85.34%, with operating and profit margins of 19.32% and 84.13%.
| Gross Margin | 85.34% |
| Operating Margin | 19.32% |
| Pretax Margin | 16.50% |
| Profit Margin | 84.13% |
| EBITDA Margin | 19.33% |
| EBIT Margin | 19.32% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.64% |
| Shareholder Yield | -11.64% |
| Earnings Yield | 8.67% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |